GSK, Pfizer, Sanofi get relief after court found claims of Zantac-linked cancer not ‘backed by science’ | The Financial Express

GSK, Pfizer, Sanofi get relief after court found claims of Zantac-linked cancer not ‘backed by science’

Zantac, first approved in 1983, became the world’s best-selling medicine in 1988 and one of the first-ever drugs to top $1 billion in annual sales.

GSK, Pfizer, Sanofi get relief after court found claims of Zantac-linked cancer not ‘backed by science’
Additionally, spokesperson for GSK said the company welcomed the decision and Pfizer said it was pleased by the outcome. (File)

GSK Plc, Pfizer Inc, Sanofi SA, and Boehringer Ingelheim on Tuesday were relieved from thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer, after a judge found the claims were not backed by sound science.

According to a report by the ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out about 50,000 claims in federal court.

However, it does not directly affect tens of thousands of similar cases pending in state courts around the country.

“We are extremely surprised by this miscarriage of justice,” and “fully expect” the ruling will be reversed on appeal, lawyers for the plaintiffs said in a joint statement as quoted by Reuters.

A Sanofi spokesperson said the decision “significantly decreases the scope of the litigation potentially by over 50%,” with the remaining litigation being only in state court. Additionally, spokesperson for GSK said the company welcomed the decision and Pfizer said it was pleased by the outcome.

Privately-held German drugmaker Boehringer said in a statement that it looked forward to “continuing our vigorous defense of the remaining cases in state courts.”

According to a report by Reuters, all the drugmakers have denied that Zantac causes cancer.

Zantac, first approved in 1983, became the world’s best-selling medicine in 1988 and one of the first-ever drugs to top $1 billion in annual sales. Originally marketed by a forerunner of GSK, it was later sold successively to Pfizer, Boehringer Ingelheim, and finally Sanofi. Numerous generic drugmakers also launched versions of the medicine, but none are defendants in the cases in federal court.

In 2019, some manufacturers and pharmacies halted sales of the drug over concerns that its active ingredient, ranitidine, degraded over time to form a chemical called NDMA. While NDMA is found in low levels in food and water, it is known to cause cancer in larger amounts.

In 2020, the U.S. Food and Drug Administration pulled all remaining brand name Zantac and generic versions off the market, citing research showing the amount of NDMA in the products increases the longer the drug is stored and could potentially become unsafe.

Reportedly, lawsuits began piling up soon after the recalls began from people who said they developed cancer after taking Zantac. Plaintiffs said the companies knew or should have known, that ranitidine posed a cancer risk and that they failed to warn consumers.

The litigation initially included claims of over 10 types of cancer allegedly linked to the medicine but was later narrowed to five – bladder, esophageal, gastrointestinal, liver, and pancreatic. Some claims involving other cancers remain in state courts.

(With inputs from Reuters)

ALSO READ | Global biopharma cos report over 9% Quarter-on-Quarter decline in market capitalisation during Q3: GlobalData

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 07-12-2022 at 15:06 IST